OIPE JC147 NOV 26 2002 PATENT & TRADEMARK OFFICE

11-27-02

RECEIVED NOV 29 2002 TECH CENTER 1600/2900

CASE 3-31105A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 195227376 US — Express Mail Label Number

November 26, 2002 — Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

MARTANI

APPLICATION NO: 10/075,429

FILED: Feb. 13, 2002

FOR: RAPIDLY DISSOLVING DOSAGE FORM AND PROCESS FOR MAKING SAME

Art Unit: 1615

Examiner: TRAN, S.

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT - A

In the Specification:

Please replace the last paragraph beginning at line 23 of page 11 with the following rewritten paragraph:

B1

The disintegration agent can be any of those known in the art, e.g., croscarmellose Na; sodium glycolates of starch, e.g., Explotab® and Primojel®; cross-linked poly-N-vinyl-2-pyrrolidones, e.g., Polyplasdone® XL and Kollidon® CL; polymethylmethacrylates, e.g., Eudispert® HV; polysaccharides, e.g., Emcosoy®; or synthetic resins, e.g., Amberlite® IRP88. Preferred disintegration agents are croscarmellose Na, sodium starch glycolate (e.g., Primojel®) and cross-linked poly-N-vinyl-2-pyrrolidones (especially Polyplasdone® XL). The disintegration agent is typically present in an amount of at least 1, preferably of at least 5, and especially of at least 10 weight-% of the total dosage form, e.g. of from 1 up to 20 weight-%, especially of from 1 up to 15 weight-%.